Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2578095 | 0.95 | HIF1A (0.40) | CTRCCYP3A4TYRHIF1AEPAS1 | |
| SCHEMBL9534596 | 0.93 | HIF1A (0.42) | CYP3A4TYRHIF1AEPAS1TDP1 | |
| SCHEMBL7295420 | 0.89 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL574954 | 0.82 | — | — | |
| Water SCHEMBL2637003 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| Butyl Alcohol SCHEMBL27800136 | 0.80 | ALDH1A1 (0.35) | GAATDP1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7471068 | 0.79 | CA2 (0.33) | CA2 | |
| SCHEMBL136808 | 0.78 | TSHR (0.38) | CYP3A4CYP2D6CYP2C9GAATDP1 | |
| SCHEMBL9303455 | 0.78 | HRH4 (0.44) | CYP2D6ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL11788637 | 0.77 | PAOX (0.34) | ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022104-A1 | AMINO COMPOUND AND METHOD FOR PRODUCING SAME, EPOXY RESIN CURING AGENT, AND EPOXY RESIN COMPOSITION AND CURED PRODUCT OF SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2026-01-22 | — | — | US | disclosed |
| US-20260008901-A1 | AMINO COMPOSITION AND METHOD FOR PRODUCING SAME, EPOXY RESIN CURING AGENT, AND EPOXY RESIN COMPOSITION AND CURED PRODUCT OF SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2026-01-08 | — | — | US | disclosed |
| EP-4592281-A1 | AMINO COMPOUND AND METHOD FOR PRODUCING SAME, EPOXY RESIN CURING AGENT, AND EPOXY RESIN COMPOSITION AND CURED PRODUCT OF SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2025-07-30 | — | — | EP | disclosed |
| EP-4592280-A1 | AMINO COMPOSITION AND METHOD FOR PRODUCING SAME, EPOXY RESIN CURING AGENT, AND EPOXY RESIN COMPOSITION AND CURED PRODUCT OF SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2025-07-30 | — | — | EP | disclosed |
| EP-1697354-B1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-1485089-B1 | COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES | MERCK SHARP & DOHME (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-1539678-B1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7960433-B2 | Treatment of chemokine mediated diseases | SCHERING CORPORATION (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1539678-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1485089-A1 | COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES | SCHERING CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION PHARMACOPEIA, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040147559-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040106794-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040097547-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | PHARMACOPEIA DRUG DISCOVERY | 2004-05-20 | — | — | US | disclosed |
| WO-2004033440-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040053953-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2004-03-18 | — | — | US | disclosed |
| WO-2004011418-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003080053-A1 | COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES | SCHERING CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | CTRC 1021/4885CYP3A4 3029/4885CYP2D6 1654/4885 |
| US-20040147559-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, CXCR1, ACKR3 | CTRC 1206/4885CYP3A4 2887/4885CYP2D6 1490/4885 |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | CTRC 721/4885CYP3A4 1187/4885CYP2D6 631/4885 |
| US-20040053953-A1 | Treatment of chemokine mediated diseases | CCR1, CXCR3, CCL11 | CTRC 1215/4885CYP3A4 2524/4885CYP2D6 1287/4885 |
| US-20040097547-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, CXCR1, ACKR3 | CTRC 1206/4885CYP3A4 2887/4885CYP2D6 1490/4885 |
| US-20040106794-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, CXCR1, ACKR3 | CTRC 1206/4885CYP3A4 2887/4885CYP2D6 1490/4885 |
| US-20260022104-A1 | AMINO COMPOUND AND METHOD FOR PRODUCING SAME, EPOXY RESIN CURING AGENT, AND EPOXY RESIN COMPOSITION AND CURED PRODUCT OF SAME | ASH2L, PRMT1, RER1 | CTRC 1313/4885CYP3A4 2988/4885CYP2D6 3508/4885 |
| US-20260008901-A1 | AMINO COMPOSITION AND METHOD FOR PRODUCING SAME, EPOXY RESIN CURING AGENT, AND EPOXY RESIN COMPOSITION AND CURED PRODUCT OF SAME | PRMT1, SRM, BCAT2 | CTRC 2801/4885CYP3A4 3386/4885CYP2D6 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.